Evidence map›Paper›PMID 37112774›Full record

ArticleVaccines2023

Safety and Immunogenicity of Enterovirus 71 Vaccine (Vero Cell) Administered Simultaneously with Trivalent Split-Virion Influenza Vaccine in Infants Aged 6-7 Months: A Phase 4, Randomized, Controlled Trial.

Yanhui Xiao, Xue Guo, Min Zhang, Yaping Chen, Yanyang Zhang, Xiaoqing Yu, Linyun Luo, Haiping Chen, Weichai Xu, Haibo Liu and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 1 country.

Yanhui XiaoMedical Affairs Department, China National Biotec Group Company Limited, No. 2, Shuangqiao Street, Chaoyang District, Beijing 100024, China.
Xue GuoMedical Affairs Department, Changchun Institute of Biological Products Company Limited, Changchun 130012, China.
Min ZhangMedical Affairs Department, China National Biotec Group Company Limited, No. 2, Shuangqiao Street, Chaoyang District, Beijing 100024, China.
Yaping ChenImmunisation Programme Department, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China.
Yanyang ZhangInstitute for Communicable Disease Control and Prevention, Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450016, China.
Xiaoqing YuInstitute of Expanded Programme on Immunization, Guizhou Provincial Center for Disease Control and Prevention, Guiyang 550004, China.
Linyun LuoMedical Affairs Department, China National Biotec Group Company Limited, No. 2, Shuangqiao Street, Chaoyang District, Beijing 100024, China.
Haiping ChenMedical Affairs Department, China National Biotec Group Company Limited, No. 2, Shuangqiao Street, Chaoyang District, Beijing 100024, China.
Weichai XuImmunisation Programme Department, Liandu District Center for Disease Control and Prevention, Lishui 323000, China.
Haibo LiuImmunisation Programme Department, Liandu District Center for Disease Control and Prevention, Lishui 323000, China.
Lixia WuImmunisation Programme Department, Boai County Center for Disease Control and Prevention, Jiaozuo 454450, China.
Renwu HouImmunisation Programme Department, Boai County Center for Disease Control and Prevention, Jiaozuo 454450, China.
Yong MaImmunisation Programme Department, Qianxinan Prefecture Center for Disease Control and Prevention, Qianxinan 562400, China.
Lin LongImmunisation Programme Department, Qianxinan Prefecture Center for Disease Control and Prevention, Qianxinan 562400, China.
Jiewei RuanMedical Affairs Department, China National Biotec Group Company Limited, No. 2, Shuangqiao Street, Chaoyang District, Beijing 100024, China.
Wei ChenMedical Affairs Department, Wuhan Institute of Biological Products Company Limited, Wuhan 430070, China.
Xiaoming YangMedical Affairs Department, China National Biotec Group Company Limited, No. 2, Shuangqiao Street, Chaoyang District, Beijing 100024, China.ORCID 0000-0002-2598-4355
Chinese Center For Disease Control and Prevention · CNXian Center for Disease Control and Prevention · CNChangchun Institute of Biological Products · CNChina National Biotechnology (China) · CNGuizhou Center for Disease Control and Prevention · CNHenan Provincial Center for Disease Control and Prevention · CNZhejiang Center for Disease Control and Prevention · CN

Funding

the China National Biotec Group EV71-2019MA-01
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

administered simultaneouslyenterovirus 71 vaccine (Vero cell)immunogenicitysafetytrivalent split-virion influenza vaccine

Identifiers

PMID37112774
PMCPMC10146551
OpenAlexW4366282356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.